P60.07 TMB and Selected Mutations in Resectable Stage IIIA NSCLC Patients Receiving Neo-Adjuvant Chemo-Immunotherapy from NADIM Trial

Authors :: M. Jove
J. Mosquera
R. Bernabe Caro
Alex Martinez-Marti
Delvys Rodriguez-Abreu
Alberto Cruz-Bermúdez
F. Franco
Alejandro Romero
M. Cobo Dols
Nuria Viñolas
R. Laza Briviesca
Ernest Nadal
M. Majem Tarruella
B. Massuti
A. Insa
E. Del Barco
M. Casarrubios
M. Provencio
Santiago Viteri
G. López Vivanco
J. De Castro Campeño
M. Domine Gomez
G. Huidobro
Isidoro Barneto
Source :: Journal of Thoracic Oncology. 16:S543
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
business.industry
Stage IIIA NSCLC
Internal medicine
medicine
Neo adjuvant
business
Chemo immunotherapy

Tools